The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...
Apr 22, 2013
0
0
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps ...
Apr 9, 2013
0
0
The central skill of cancer is its ability to mutate – that's how it became cancerous in the first place. Once it's started down that path, it's not so difficult for a cancer cell to mutate again and again. This means that ...
Dec 1, 2012
0
0
Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib ...
Nov 15, 2012
0
0
A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit ...
Oct 15, 2012
0
0
DENVER- In lung cancer, patients who benefit from drugs like erlotinib will inevitably develop drug resistance. This is heralded by cancer growth and increasing tumor-related symptoms. Now scientists are investigating a second ...
Jul 25, 2012
0
0
The addition of high doses of erlotinib to the treatment regimen of bevacizumab and capecitabine with radiotherapy seems to benefit patients with locally advanced pancreatic cancer, according to results of a phase I study ...
Jun 19, 2012
0
0
Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed ...
Jun 1, 2012
0
1
Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd ...
Apr 18, 2012
0
0
Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head ...
Jan 26, 2012
0
0
